Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case

Impact · against what's priced in

Poolbeg Pharma gains incremental value from extended patent protection in South Korea, enhancing the asset's long-term licensing appeal. Gelion receives a positive catalyst via a new evaluation deal with a top-15 global automaker, while Johnson & Johnson remains unaffected.

GELN+0.70

No priced-in read yet

In context

Securing an evaluation deal with a top-15 global automaker validates the commercial viability of its sulfur battery cathode technology.

Read from the article alone

• biotech
• GELN
• POLB
• automotive
• battery tech
• cancer
• clinical trials
• ev
• immunotherapy
• patents
• pharma